Research

Estimates

SA Earngings
MB Earnings
Yahoo Earnings
CNBC Earnings
Barrons Earnings

Ratings

SA Ratings
MB Ratings
BC Ratings
TR Ratings
Fidelity

Short Interest

MB Shorts
Quandl

Smart Money

MB Institutional
Gurus

Options

BC Options Ratio

Financials

GuruFocus Summary

Social

Stocktwits
MB Social
SocialSentiment.com
Twitter
Yahoo
Facebook
Reuters
Google

Misc

Tickeron
Ycharts NAV +/-

Beam Therapeutics Inc. Common Stock | BEAM

Daily Technical Analysis of Beam Therapeutics Inc. Common Stock

Beam Therapeutics moved up less than 1% today. The market isn't being very decisive in its valuation of asset.

Currently BEAM isn't at a clear support/resistance line that seems tradable. Momentum wise Beam Therapeutics , has been oscillating up and down but hasn't shown much directional energy that would be predictive to the near future. It may keep moving up to $46.56 and hit some selling pressure. Hard to say though...


Last analyzed on 2024-02-28

Analyst Ratings for Beam Therapeutics By Price Target And Rating

The balance of viewpoints by the analysts is positive. The current Analysts Sentiment Score is 80.67. Most companies range between (-200 to 200).

Here's a break down of the latest rating changes. Royal Bank of Canada gave a boost to their price target and moved to $35.00 from $27.00 on 2024-02-28. On 2024-02-28 Barclays increased their price target by 61.54% to $42.00. On 2024-02-27 there was confirmation of the previous rating by Wedbush which was Outperform and also increased their price target by 18.75% to $57.00. JPMorgan Chase & Co. announced an upgrade on 2024-01-29 from Neutral to Overweight and provided a price target boost 5.26% to $40.00 from $38.00. Bank of America released a downgrade on 2023-12-15 from Buy to Neutral and added a price target of $35.00. Jefferies Financial Group reiterated a rating of Buy on 2023-12-08 and they lowered their price target by -60% to $30.00 from a previous target of $75.00. William Blair reiterated a rating of Outperform on 2023-10-31. On 2023-10-20 there was a downgrade announced by SVB Leerink from Outperform to Market Perform and dropped their 1 year price target to $20.00 which is down from $75.00. Cantor Fitzgerald released a downgrade on 2023-10-20 from Overweight to Neutral. Leerink Partnrs downgraded from Outperform to Market Perform on 2023-10-20.

Company Ratings Score ?
Composite analyst sentiment score
Positive Ratings Negative Ratings Boost Price Target Lower Price Target
BEAM80.67192.24-149.31200.45-82.04

Earnings Per Share (EPS) Estimates By Year and Quarter

(updated 2024-03-01)
Company YOY Growth Score (typical -20 to +20) Revision Directions (-6 to +6)
BEAM-20.76-11.36

Short interest for Beam Therapeutics

We take into account several different measures of short interest to create a composite score. These measures are shown in the chart below. Short selling is when investors are betting against a stock. We compile these factors to create a dynamic Short Score - this can indicate poor sentiment, internal problems with a company or industry and the anticipation of future price declines. We look at the short interest percent, days to cover, the rate of change and total shares sold short.

Company Short Score (typical 1-15) ?
We take into account several different measures and attributes of short interest to create a composite sentiment score. typical range (0 - 30)
Short Interest Days to Cover Rate of Change Shares Short
BEAM18.78%19.065716.310.95615100000

Social Sentiment for Beam Therapeutics

Social Sentiment is an aggregation of several different factors such as news, articles, blogs, user content, ratings, etc. Which is shown in the chart below. It may become predictive of a reversal if price and the sentiment diverge. Broader market forces may push prices up or down but if market participants maintain a different view on a specific stock, it may be taken as an opportunity to buy or sell in those cases.

Ticker Social Sentiment(1-10)
BEAM

Companies with the highest correlation to Beam Therapeutics

Company Score 1 Day% 5 Day 1 Month 3 Month 6 Month 1 Year RSI 3mo S-momo ? 6mo S-momo 1yr S-momo Resistance ? Support Demark Sell ? Demark Buy Short Interest Score
EDIT | Editas Medicine, Inc. Com1.614.6730.6548.10-4.1018.1820.7663-5.28-8.48-10.01-25289.59-1564.500016.4101
NTLA | Intellia Therapeutics, In1.471.6818.0829.149.23-12.86-25.7658-9.60-21.67-36.94-43032.54-842.240010.4627
TWST | Twist Bioscience Corporat1.43-1.02-4.196.2957.6476.85105.7758151.0943.2081.42-1223.61-11313.410023.3961
VCYT | Veracyte, Inc.1.321.911.87-3.34-5.47-9.09-0.41361.362.147.88-10492.59-2818.57004.97884
CRSP | CRISPR Therapeutics AG1.3-0.56-2.6829.3418.6365.7875.507140.7625.8722.620.00-15593.94150015.3247
RCKT | Rocket Pharmaceuticals, I1.284.202.486.9420.6295.0848.066396.3357.3946.08-483.68-24270.72009.12889
MTLS | Materialise NV1.22-0.37-2.18-5.61-17.10-20.41-38.3036-22.51-24.87-30.01-41389.07-3.41000.983039

Top 3 correlating companies

See full charts for all peers

Sentiment Score

How to use: use the research links to research the asset. Then simply type in a score for each category between (01, 02, 03, 04, 05). 05 being the most bullish and 01 being the most bearish. It will automatically calculate the average and combine it with the technical score to create an overall score to rank prospects by. You can also type notes into each field.

Earnings Estimates
Analyst Rating
Price Targets
Short Interest
Financials
Options Sentiment
Institutional Ownership
Social Sentiment
Fidelity Summary
Overall Summary Notes
Calculated Sentiment Sum

Score Sum
(1-45)

/

Average
(1-5)

+

Pattern Rank
(1-5)

=

Total Score
(1-10)

Research

Estimates

SA Earngings
MB Earnings
Yahoo Earnings

Ratings

SA Ratings
MB Ratings
BC Ratings
TR Ratings
Fidelity

Short Interest

MB Shorts
Quandl

Smart Money

MB Institutional
Gurus

Options

BC Options Ratio

Financials

GuruFocus Summary

Social

MB Social
SocialSentiment.com
Twitter
Yahoo
Facebook
Reuters
Google

Misc

Tickeron
Ycharts NAV +/-